Literature DB >> 25713801

Immunoregulation by lipids during the development of non-alcoholic steatohepatitis.

Pierluigi Ramadori1, Daniela Kroy1, Konrad L Streetz1.   

Abstract

Non-alcoholic fatty liver disease (NAFLD) represents the most common liver disorder in western countries and it is commonly associated with obesity and progression of the metabolic syndrome. Comprehending a wide spectrum of pathologic features, it is currently well recognized that a key point for the integrity of hepatocyte functionality in NAFLD is the progression from simple steatosis to non-alcoholic steatohepatitis (NASH). Indeed, activation of the innate immune system in response to hepatic metabolic stresses represents a central process that determines the evolution and the reversibility of liver damage. Despite of the burden of studies published in recent years, it is still intriguingly unclear how accumulation of lipids in hepatocytes triggers the activation of the inflammatory response leading to the recruitment of infiltrating cells of extra-hepatic origins. In this review we offer a general view on recent advances pointing out how different classes of lipids are able to specifically affect hepatocytes functionality and survival, thus differently influencing the organization of the hepatic immune response. On the other hand, we gathered recent studies intending to illustrate the basic mechanisms through which several non-parenchymal hepatic and extra-hepatic cell populations get activated in response to lipids. Finally, we indicate latter findings proposing how the immune system majorly contributes to the progression of NASH.

Entities:  

Keywords:  Hepatocyte; free fatty acids (FFA); lipotoxicity; lymphocytes; toll like receptors (TLRs)

Year:  2015        PMID: 25713801      PMCID: PMC4318957          DOI: 10.3978/j.issn.2304-3881.2015.01.02

Source DB:  PubMed          Journal:  Hepatobiliary Surg Nutr        ISSN: 2304-3881            Impact factor:   7.293


  97 in total

Review 1.  Hepatic triacylglycerol accumulation and insulin resistance.

Authors:  Cynthia A Nagle; Eric L Klett; Rosalind A Coleman
Journal:  J Lipid Res       Date:  2008-11-06       Impact factor: 5.922

2.  Hepatocyte free cholesterol lipotoxicity results from JNK1-mediated mitochondrial injury and is HMGB1 and TLR4-dependent.

Authors:  Lay T Gan; Derrick M Van Rooyen; Mark E Koina; Robert S McCuskey; Narcissus C Teoh; Geoffrey C Farrell
Journal:  J Hepatol       Date:  2014-07-24       Impact factor: 25.083

3.  Modulation of non-alcoholic steatohepatitis by pattern recognition receptors in mice: the role of toll-like receptors 2 and 4.

Authors:  Gyongyi Szabo; Arumugam Velayudham; Laszlo Romics; Pranoti Mandrekar
Journal:  Alcohol Clin Exp Res       Date:  2005-11       Impact factor: 3.455

4.  Triglyceride accumulation protects against fatty acid-induced lipotoxicity.

Authors:  Laura L Listenberger; Xianlin Han; Sarah E Lewis; Sylvaine Cases; Robert V Farese; Daniel S Ory; Jean E Schaffer
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-10       Impact factor: 11.205

5.  Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions.

Authors:  E M Brunt; C G Janney; A M Di Bisceglie; B A Neuschwander-Tetri; B R Bacon
Journal:  Am J Gastroenterol       Date:  1999-09       Impact factor: 10.864

6.  Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2.

Authors:  John Willy Haukeland; Jan Kristian Damås; Zbigniew Konopski; Else Marit Løberg; Terese Haaland; Ingeborg Goverud; Peter A Torjesen; Kåre Birkeland; Kristian Bjøro; Pål Aukrust
Journal:  J Hepatol       Date:  2006-03-20       Impact factor: 25.083

7.  Inflammasome-mediated secretion of IL-1β in human monocytes through TLR2 activation; modulation by dietary fatty acids.

Authors:  Ryan G Snodgrass; Shurong Huang; Il-Whan Choi; John C Rutledge; Daniel H Hwang
Journal:  J Immunol       Date:  2013-09-16       Impact factor: 5.422

8.  Liver NF-kappaB and AP-1 DNA binding in obese patients.

Authors:  Luis A Videla; Gladys Tapia; Ramón Rodrigo; Paulina Pettinelli; Daniela Haim; Catherine Santibañez; A Verónica Araya; Gladys Smok; Attila Csendes; Luis Gutierrez; Jorge Rojas; Jaime Castillo; Owen Korn; Fernando Maluenda; Juan C Díaz; Guillermo Rencoret; Jaime Poniachik
Journal:  Obesity (Silver Spring)       Date:  2009-01-22       Impact factor: 5.002

9.  Inhibition of de novo ceramide synthesis reverses diet-induced insulin resistance and enhances whole-body oxygen consumption.

Authors:  John R Ussher; Timothy R Koves; Virgilio J J Cadete; Liyan Zhang; Jagdip S Jaswal; Suzanne J Swyrd; David G Lopaschuk; Spencer D Proctor; Wendy Keung; Deborah M Muoio; Gary D Lopaschuk
Journal:  Diabetes       Date:  2010-06-03       Impact factor: 9.461

10.  Internalization of modified lipids by CD36 and SR-A leads to hepatic inflammation and lysosomal cholesterol storage in Kupffer cells.

Authors:  Veerle Bieghs; Fons Verheyen; Patrick J van Gorp; Tim Hendrikx; Kristiaan Wouters; Dieter Lütjohann; Marion J J Gijbels; Maria Febbraio; Christoph J Binder; Marten H Hofker; Ronit Shiri-Sverdlov
Journal:  PLoS One       Date:  2012-03-28       Impact factor: 3.240

View more
  17 in total

1.  Berberine attenuates non-alcoholic steatohepatitis by regulating chemerin/CMKLR1 signalling pathway and Treg/Th17 ratio.

Authors:  Zengsheng Lu; Fengbin Lu; Liyan Wu; Beihui He; Zhiyun Chen; Maoxiang Yan
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2020-06-10       Impact factor: 3.000

Review 2.  Dietary and metabolic modulators of hepatic immunity.

Authors:  Antonella Carambia; Johannes Herkel
Journal:  Semin Immunopathol       Date:  2017-11-06       Impact factor: 9.623

3.  Phosphatidylcholine transfer protein/StarD2 promotes microvesicular steatosis and liver injury in murine experimental steatohepatitis.

Authors:  Hayley T Nicholls; Jason L Hornick; David E Cohen
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2017-04-06       Impact factor: 4.052

Review 4.  Innate Immunity and Inflammation in NAFLD/NASH.

Authors:  Marco Arrese; Daniel Cabrera; Alexis M Kalergis; Ariel E Feldstein
Journal:  Dig Dis Sci       Date:  2016-02-03       Impact factor: 3.199

Review 5.  Genetic, metabolic and environmental factors involved in the development of liver cirrhosis in Mexico.

Authors:  Omar Ramos-Lopez; Erika Martinez-Lopez; Sonia Roman; Nora A Fierro; Arturo Panduro
Journal:  World J Gastroenterol       Date:  2015-11-07       Impact factor: 5.742

6.  EFFECT OF DORSOMEDIAL HYPOTHALAMUS NEUROPEPTIDE Y KNOCKDOWN ON HEPATIC INSULIN SENSITIVITY.

Authors:  Z Cui; Q Qin; P Chen; J Wang; S Zhang; X Mei; B Xie; S Wang
Journal:  Acta Endocrinol (Buchar)       Date:  2019 Jan-Mar       Impact factor: 0.877

Review 7.  Mechanisms Linking Inflammation to Insulin Resistance.

Authors:  Li Chen; Rui Chen; Hua Wang; Fengxia Liang
Journal:  Int J Endocrinol       Date:  2015-06-02       Impact factor: 3.257

8.  Linarin Enriched Extract Attenuates Liver Injury and Inflammation Induced by High-Fat High-Cholesterol Diet in Rats.

Authors:  Zhen-Jie Zhuang; Chao-Wen Shan; Bo Li; Min-Xia Pang; Han Wang; Yan Luo; Yin-Lan Liu; Yu Song; Nan-Nan Wang; Su-Hong Chen; Jun-Ping Shi; Gui-Yuan Lv
Journal:  Evid Based Complement Alternat Med       Date:  2017-06-27       Impact factor: 2.629

9.  A new use for an old index: preoperative high-density lipoprotein predicts recurrence in patients with hepatocellular carcinoma after curative resections.

Authors:  Lu Tian; Qian Yu; Xing-Hui Gao; Jiong Wu; Xiao-Lu Ma; Qian Dai; Chun-Yan Zhang; Yan Zhou; Yi-Chi Zhang; Bai-Shen Pan; Jian Zhou; Jia Fan; Xin-Rong Yang; Wei Guo
Journal:  Lipids Health Dis       Date:  2017-06-26       Impact factor: 3.876

10.  In Situ Evaluation of Oxidative Stress in Rat Fatty Liver Induced by a Methionine- and Choline-Deficient Diet.

Authors:  Isabel Freitas; Eleonora Boncompagni; Eleonora Tarantola; Cristian Gruppi; Vittorio Bertone; Andrea Ferrigno; Gloria Milanesi; Rita Vaccarone; M Enrica Tira; Mariapia Vairetti
Journal:  Oxid Med Cell Longev       Date:  2016-01-06       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.